Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

Original reporting
Published Nov 13, 2026, 7:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 7:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Curis (CRIS) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CRISBullishMed
01

Why it matters

Earnings show narrowing losses and ongoing trial enrollment, which may improve investor sentiment.

02

Market read

Primary earnings release for a micro‑cap biotech; relevance mainly to sector and CRIS shareholders.

03

What to watch

Potential regulatory delays for emavusertib and competition from other BTK inhibitor combos.

Relevance 7/10Novelty 7/10Timing: after‑hours earnings release

Background

Curis (CRIS) is a clinical‑stage biotech developing emavusertib for BTK‑resistant cancers.

Company-level read

Ticker impact

$CRISBullishHigh confidence
Context

Curis reported Q3 2026 net loss of $8.1M ($1.94 per share) and updated clinical trial progress, a fresh earnings disclosure.

Expected impact

likely modest upside as loss per share improves and trial updates may boost confidence

Evidence & confidence

The per‑share loss narrowed sharply from $9.86 to $1.94, indicating better cost control and potential future revenue from emavusertib trials.

Market effects

Biotech sector may see slight uplift as a small‑cap trial update shows progress.

US biotech investors may adjust positions; limited broader market effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Losses remain sizable; cash runway limited; risk of dilution could outweigh upside.

Key entities

  • Curis

    Biotech firm developing emavusertib.

  • Emavusertib

    Investigational therapy targeting TLR pathway.

Related articles

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

$CRISMedAI 8/10

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.